Spermosens and Sapyen sign Memorandum of Understanding to advance male fertility diagnostics
Male fertility diagnostics is undergoing a structural shift, driven by increasing demand for patient-friendly access combined with clinical-grade data. Sapyen has established a model that enables home-based sample collection while maintaining compatibility with laboratory-grade analysis, supporting integration into established fertility care pathways. Against this background, the MoU aims to assess how JUNO-Checked could complement and extend such diagnostic services by providing additional, clinically relevant insight into male fertility potential.
The intention of the MoU is to provide a structured framework under which the parties aim to evaluate a business model where Sapyen could take a leading role in commercial activities, supported by Spermosens’ diagnostic technology. During the term of the MoU, the parties intend to assess commercial, operational and regulatory aspects relevant to a potential collaboration.
